Sol Gel Technologies
Yahoo Finance • 28 days ago
Sol-Gel announces Health Canada approval of EPSOLAY
* Sol-Gel Technologies (NASDAQ:SLGL [https://seekingalpha.com/symbol/SLGL]) said on Thursday that Health Canada has issued [https://seekingalpha.com/pr/20220823-sol-gel-announces-health-canada-approval-of-epsolay] a Notice of Compliance... Full story
Yahoo Finance • 2 months ago
Sol Gel Tech earnings beat by $4.84, revenue topped estimates
Investing.com - Sol Gel Tech (NASDAQ: SLGL) reported second quarter EPS of $4.1700, $4.84 better than the analyst estimate of $-0.6700. Revenue for the quarter came in at $17.26M versus the consensus estimate of $2.86M. Sol Gel Tech’s sto... Full story
Yahoo Finance • 2 months ago
Sol-Gel Technologies GAAP EPS of -$1.57, revenue of $5.89M
* Sol-Gel Technologies press release [https://seekingalpha.com/pr/20202388-sol-gel-reports-second-quarter-2025-financial-results-and-provides-corporate-updates] (NASDAQ:SLGL [https://seekingalpha.com/symbol/SLGL]): Q2 GAAP EPS of -$1.57.... Full story
Yahoo Finance • 2 months ago
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease... Full story
Yahoo Finance • 4 months ago
Sol-Gel Reports First Quarter 2025 Results
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for th... Full story
Yahoo Finance • 6 months ago
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results a... Full story
Yahoo Finance • 2 years ago
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
SGT-610 has “Orphan Drug” designation status in the U.S. and E.U. and “Breakthrough Therapy” designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in Gorlin syndromeSol-Gel to host a virtual... Full story
Yahoo Finance • 2 years ago
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE... Full story
Yahoo Finance • 2 years ago
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains cash runway into the second half of 2025... Full story
Yahoo Finance • 2 years ago
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with t... Full story
Yahoo Finance • 2 years ago
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib)for Gorlin syndrome into Phase 3 t... Full story
Yahoo Finance • 3 years ago
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced t... Full story
Yahoo Finance • 3 years ago
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome A Phase 3 study of SGT-61... Full story
Yahoo Finance • 3 years ago
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products that wer... Full story
Yahoo Finance • 3 years ago
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA Phase 3 study expected to initiate in the secon... Full story
Yahoo Finance • 3 years ago
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribers Sol-Gel’s cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE... Full story
Yahoo Finance • 3 years ago
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Prescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel receives $3.5 million milestone payment from commercial partner Galderma Holding SA (“Galderma”)for FDA approval of EPSOLAY Sol-Gel’s... Full story
Yahoo Finance • 3 years ago
Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the tr... Full story
Yahoo Finance • 3 years ago
Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the tre... Full story
Yahoo Finance • 3 years ago
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%)represents Sol-Gel’ssecond approved product within less than a year;EPSOLAY is patent protected until 2040 Partner Galderma to launch two products in the U.S. this quarter: TWYNEO laun... Full story
